Monday, June 21, 2010

"Female Viagra" Not Quite Ready for Prime Time

What has been dubbed the "Female Viagra" does not show signs of being effective according to the Food and Drug Administration (FDA). An advisory committee for the FDA advised the drug’s manufacturer, Boehringer Ingelheim, to "go back to the drawing board" and provide more conclusive data. The little pink pill's name is flibanserin and has been touted as the answer to low sex drive in women. The drug's manufacturer used some interesting wording to describe the drug’s effect: "It’s better at increasing a woman’s global desire rather than the intensity of acute episodes of desire." HUH? I think that’s bureaucratic speak for the drug is "iffy" at best. Global desire? Acute episodes of desire? Is that orgasm? Get to the point, Boehringer Ingelheim!

Original designed to help battle depression, the drug's side effects were significant in that 15% of the women in the clinical trial experienced the effects to such a degree that they stopped the trial due to dizziness, anxiety, insomnia, and nausea.

At the time of this writing, there is not one FDA-approved drug on the market designed to improve women's sexual dysfunction or to help overcome a lack of sexual desire.

However, we all know how many options men have these days. Viagra, Cialis, Levitra…
If you have taken a drug that has caused harmful side effects, please contact the pharmaceutical litigation attorneys at Schlichter, Bogard & Denton today to schedule a confidential consultation.

posted by Lynn at 9:22 AM

Archives

Drug Injury and Recall Blog

Dangerous and Defective Pharmaceutical Products

1.800.873.5297 Email Us

Welcome to the dangerous prescription drugs website of Schlichter, Bogard & Denton,
please upgrade your Flash Plugin and enable JavaScript to see our pharmaceutical injury video.